Invivoscribe CE-IVD LymphoTrack Dx Assays

Invivoscribe Technologies has launched three new CE-marked in vitro diagnostic assays for the company's Ion PGM Dx System. The new assays include an IGH, IGK, and TRG clonality assays to aid in the diagnosis of B-cell malignancies. When the IGH and IGK assays are used together, it's possible to detect clonality in a majority of B-cell malignancies with nearly 100 percent clinical sensitivity, the company said. Additionally, when all three assays are used together, it is possible to detect a least one clonal biomarker target in the vast majority of hematologic malignancies, the company said.